As part of the perocess for FDA's AA REVASCOR approval, there will likely be the requirement that a confirmatory trial plan needs to be presented, or in fact will have been presented.
Is it therefore reasonable to say that MSB would have sought partnership (and as per communicated intentio), to be (to have been) able to convince/reassure FDA, the confirmatory trial is adequately planned and prepared? I.e., in a sense we can expect to hear from some partnership news following (at the same time even?) as FDA AA news?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
-0.030(1.80%) |
Mkt cap ! $2.095B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.62 | $23.20M | 14.15M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 217849 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 69336 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |